DHAP regimen: Difference between revisions
Created page with "__NOTOC__ {{SI}} {{CMG}}; {{AE}} {{AV}} {{SK}} ==Overview== {{PAGENAME}} refers to a chemotherapy regimen consisting of dexamethasone, high-dose cytarabine|cytarabine..." |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
{{SI}} | {{SI}} | ||
{{CMG}}; {{AE}} {{AV}} | {{CMG}}; {{AE}} {{AV}} | ||
==Overview== | ==Overview== | ||
{{PAGENAME}} refers to a chemotherapy regimen consisting of [[dexamethasone]], high-dose [[cytarabine|cytarabine (Ara-C)]] and [[cisplatin]], used to treat relapsed and refractory [[non-Hodgkin's|non-Hodgkin's | {{PAGENAME}} refers to a chemotherapy regimen consisting of [[dexamethasone]], high-dose [[cytarabine|cytarabine (Ara-C)]] and [[cisplatin]], used to treat relapsed and refractory [[non-Hodgkin's lymphoma|non-Hodgkin's]] and [[Hodgkin's lymphoma]].<ref name="pmid3334893">{{cite journal| author=Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S et al.| title=Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). | journal=Blood | year= 1988 | volume= 71 | issue= 1 | pages= 117-22 | pmid=3334893 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3334893 }} </ref> | ||
==Regimen== | ==Regimen== | ||
{{chemo|D|Dexamethasone}} | {{chemo|D|Dexamethasone}} | ||
High | {{chemo|H|High Dose}} | ||
{{chemo|A|Cytarabine (Ara-C)}} | {{chemo|A|Cytarabine (Ara-C)}} | ||
{{chemo|P|Cisplatin}} | {{chemo|P|Cisplatin}} | ||
==Indications== | ==Indications== | ||
*[[Non-Hodgkin's lymphoma]] | *[[Non-Hodgkin's lymphoma]] | ||
*[[Hodgkin's lymphoma]] | *[[Hodgkin's lymphoma]]<ref name="pmid3334893">{{cite journal| author=Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S et al.| title=Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). | journal=Blood | year= 1988 | volume= 71 | issue= 1 | pages= 117-22 | pmid=3334893 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=3334893 }} </ref> | ||
==References== | ==References== | ||
Latest revision as of 18:15, 12 March 2015
|
WikiDoc Resources for DHAP regimen |
|
Articles |
|---|
|
Most recent articles on DHAP regimen Most cited articles on DHAP regimen |
|
Media |
|
Powerpoint slides on DHAP regimen |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on DHAP regimen at Clinical Trials.gov Clinical Trials on DHAP regimen at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on DHAP regimen
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on DHAP regimen Discussion groups on DHAP regimen Patient Handouts on DHAP regimen Directions to Hospitals Treating DHAP regimen Risk calculators and risk factors for DHAP regimen
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for DHAP regimen |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
DHAP regimen refers to a chemotherapy regimen consisting of dexamethasone, high-dose cytarabine (Ara-C) and cisplatin, used to treat relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.[1]
Regimen
DDexamethasone
HHigh Dose
ACytarabine (Ara-C)
PCisplatin
Indications
References
- ↑ 1.0 1.1 Velasquez WS, Cabanillas F, Salvador P, McLaughlin P, Fridrik M, Tucker S; et al. (1988). "Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)". Blood. 71 (1): 117–22. PMID 3334893.